PharmaEngine (TWO:4162) — Market Cap & Net Worth
Market Cap & Net Worth: PharmaEngine (4162)
PharmaEngine (TWO:4162) has a market capitalization of $243.71 Million (NT$7.74 Billion) as of September 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #15846 globally and #718 in its home market, demonstrating a -3.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying PharmaEngine's stock price NT$54.60 by its total outstanding shares 141677000 (141.68 Million). Also see 4162 asset base for a full breakdown of the balance sheet.
PharmaEngine Market Cap History: 2015 to 2026
PharmaEngine's market capitalization history from 2015 to 2026. Data shows change from $629.29 Million to $243.71 Million (-7.47% CAGR). Also see PharmaEngine (4162) cash flow conversion for how efficiently the company converts equity into cash flow.
PharmaEngine Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how PharmaEngine's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check PharmaEngine (4162) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.16x
PharmaEngine's market cap is 0.16 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.23x
PharmaEngine's market cap is 0.23 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $629.29 Million | $507.24 Million | $394.02 Million | 1.24x | 1.60x |
| 2016 | $573.98 Million | $1.13 Billion | $689.62 Million | 0.51x | 0.83x |
| 2017 | $584.01 Million | $853.68 Million | $387.06 Million | 0.68x | 1.51x |
| 2018 | $439.37 Million | $293.43 Million | $129.36 Million | 1.50x | 3.40x |
| 2019 | $270.03 Million | $314.04 Million | $42.55 Million | 0.86x | 6.35x |
| 2020 | $229.86 Million | $1.06 Billion | $604.28 Million | 0.22x | 0.38x |
| 2021 | $300.95 Million | $654.84 Million | $426.03 Million | 0.46x | 0.71x |
| 2022 | $534.67 Million | $654.38 Million | $318.78 Million | 0.82x | 1.68x |
| 2023 | $462.64 Million | $767.67 Million | $274.65 Million | 0.60x | 1.68x |
| 2024 | $403.06 Million | $2.52 Billion | $1.75 Billion | 0.16x | 0.23x |
Competitor Companies of 4162 by Market Capitalization
Companies near PharmaEngine in the global market cap rankings as of September 18, 2026. Review PharmaEngine (4162) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to PharmaEngine by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
PharmaEngine Historical Marketcap From 2015 to 2026
Between 2015 and today, PharmaEngine's market cap moved from $629.29 Million to $ 243.71 Million, with a yearly change of -7.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$243.71 Million | -22.44% |
| 2025 | NT$314.24 Million | -22.04% |
| 2024 | NT$403.06 Million | -12.88% |
| 2023 | NT$462.64 Million | -13.47% |
| 2022 | NT$534.67 Million | +77.66% |
| 2021 | NT$300.95 Million | +30.93% |
| 2020 | NT$229.86 Million | -14.88% |
| 2019 | NT$270.03 Million | -38.54% |
| 2018 | NT$439.37 Million | -24.77% |
| 2017 | NT$584.01 Million | +1.75% |
| 2016 | NT$573.98 Million | -8.79% |
| 2015 | NT$629.29 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of PharmaEngine was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $243.71 Million USD |
| MoneyControl | $243.71 Million USD |
| MarketWatch | $243.71 Million USD |
| marketcap.company | $243.71 Million USD |
| Reuters | $243.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About PharmaEngine
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematol… Read more